COVID-19 Trials

Adaptive COVID-19 Treatment Trial 3 (ACTT-III), NIH

PI – Dr. Diego Lopez de Castilla

Goal: To evaluate the safety and efficacy, as assessed by time to recovery, of the combination of interferon beta-1a and remdesivir compared to remdesivir alone.

• Phase III, randomized, double-blind, placebo-controlled trial.
• Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29.
• Multicenter trial with 100 centers globally and 1038 subjects enrollment goal.

---

Boca Biolistics

Protocol #: CRSPTL-00012
PI – Dr. Diego Lopez de Castilla

Goal: Procure plasma and/or serum and other sample types from up to approximately 5,000 study subjects diagnosed positive for acute or chronic tropical or infectious diseases to evaluate the performance of new investigational devices or therapeutics.

• 5000 samples worldwide.
• EvergreenHealth providing 200 patient samples to evaluate antibodies in COVID-19 +ve patients.

---

Cue Health

PI – Dr. Chad Crystal

Goal: Perform a pre-clinical external site research evaluation of the Cue COVID-19 Test compared to the institutional standard of care SARS CoV-2 test.

• Point-of-care test conducted by healthcare professional with a proprietary Cue nasal swab.
• Test result in 25 minutes using the Cue Cartridge Reader, Cue COVID-19 Test Cartridge, and the Cue Health App on a mobile smart device (iPhone).